 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
GeneDx Holdings Corp. (WGS), through its subsidiaries, provides genomics-related diagnostic and information services.
The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Please note this stock reports earnings today, July 30th, at market close.
GeneDx reported a loss of $0.33 per share on revenue of $62.42 million for the first quarter ended March 2024. The consensus estimate was a loss of $0.68 per share on revenue of $49.80 million. The company beat consensus estimates by 51.47% while revenue grew 44.70% on a year-over-year basis.
The company said it expects 2024 revenue of $235.0 million to $245.0 million. The company's previous guidance was revenue of $220.0 million to $230.0 million and the current consensus revenue estimate is $226.90 million for the year ending December 31, 2024.
Entry Point: $33.50
Trading Range: $1.16 - $35.65
Stop Loss: $31.80
Target Price: $36.85
